Preserve
what makes
it biology.
The next era of medicine needs materials it can depend on. We’re building the way to make them.
Explore the materialOur starting materialNative-derived Type I collagen
Our stageLab development · working toward scale
Another batch.
Another
set of questions.
When biological inputs vary, researchers have to characterize and qualify them again. Progress waits on the material.
- Receive a new batch
A new material input enters your workflow.
- Characterize the material
Check its properties against your requirements.
- Confirm suitability
Decide whether it is fit for your experiment.
Dependable inputs could give that time back.
Three chains.
A world
of function.
Collagen’s native architecture is a triple helix. Extraction has to release the material while preserving the structure that makes it useful.
Three polypeptide chains, wound around a shared axis.
Release the
material.
Keep its nature.
M.A.S.S. is our process for isolating native-derived Type I collagen. Lab results support retention of its triple-helical structure.
Scroll to watch the surrounding matrix separate from the collagen core. ECM architecture and molecular scale are compressed into one conceptual view.
Keep your
research moving.
with our materialsDeveloping applications in research and regenerative medicine.
Make it once.
Learn to make
it reliably.
The next step is a manufacturing system that delivers controlled, characterized batches. Application validation, licensing and repeatable production are the milestones ahead.
Better materials.
More possible.
From tissue engineering to organoids and bioinks, we’re working toward a dependable starting point for people building what comes next.
Building toward
a base in Japan.
Our plan is to establish Avenyx in Japan and pursue a patent filing there. A Japanese company with a global ambition: dependable native biomaterials for research and regenerative medicine.
